Lantus (Insulin Glargine) Safety During Breastfeeding and Colostrum Production
All types of insulin, including Lantus (insulin glargine), can be safely used by breastfeeding women, including during the colostrum production phase. 1
Safety Profile During Lactation
Insulin does not transfer into breast milk in clinically significant amounts because it is a large peptide molecule that is poorly absorbed from the gastrointestinal tract, making it safe for the nursing infant. 2, 3
Multiple diabetes guidelines explicitly state that all insulin formulations, including Lantus, are compatible with breastfeeding without restrictions. 1
There is no need to discontinue or switch insulin therapy specifically for breastfeeding—women can continue their established insulin regimen. 3
Postpartum Insulin Management Considerations
Immediate Postpartum Period
Insulin requirements drop dramatically after delivery (approximately 34% lower than prepregnancy requirements), with insulin sensitivity returning to baseline over 1-2 weeks postpartum. 1
Close monitoring of blood glucose is essential in the immediate postpartum period if receiving insulin to prevent hypoglycemia. 1
Breastfeeding-Specific Adjustments
Lactation increases the risk of hypoglycemia, particularly overnight, due to the glucose demands of milk production. 1
Insulin dosing may need to be reduced during the breastfeeding period compared to prepregnancy doses. 2
Ensure adequate carbohydrate intake to support both lactation and prevent hypoglycemia while on insulin. 2
Clinical Management Algorithm
For women with gestational diabetes:
- Discontinue all diabetes medications immediately postpartum, as most return to normal glucose tolerance. 1
- Perform glucose testing at 4-12 weeks postpartum to assess persistent diabetes. 1
For women with preexisting Type 1 or Type 2 diabetes:
- Continue insulin therapy throughout breastfeeding without interruption. 1, 3
- Reduce insulin doses immediately postpartum (typically to 50-66% of late pregnancy doses) and titrate based on blood glucose monitoring. 1
- Monitor for hypoglycemia, especially during nighttime feedings. 1
- Adjust doses based on erratic sleep and eating schedules common in the postpartum period. 1
Important Caveats
Do not delay or withhold necessary insulin therapy due to breastfeeding concerns—the benefits of breastfeeding are substantial for both mother and infant, and insulin is fully compatible with lactation. 1, 3
Women with Type 2 diabetes on oral agents (metformin, glibenclamide) can continue these medications while breastfeeding as alternatives to insulin, though insulin remains the optimal choice when glycemic control requires it. 1, 3
Monitor the mother for ketones, as acetone can be excreted in breast milk and may affect the infant. 2
The neonate of a diabetic mother requires pediatric assessment for hypoglycemia risk after delivery. 1